Pharmaceuticals company Solara Active Pharma Sciences announced Q1FY27 results Consolidated Financial Highlights: Total income for Q1FY27 was Rs 384.29 crore, representing a YoY increase of 20.04% from Rs 320.13 crore in Q1FY26, and a QoQ decrease of 1.96% from Rs 391.98 crore in Q4FY26. Revenue from operations stood at Rs 381.60 crore in Q1FY27, reflecting a growth of 19.57% compared to Rs 319.15 crore in Q1FY26, and a marginal decline of 1.47% from Rs 387.29 crore in Q4FY26. Other income for Q1FY27 was Rs 2.69 crore, as against Rs 0.98 crore in Q1FY26 and Rs 4.69 crore in Q4FY26. Profit before tax for Q1FY27 reached Rs 16.31 crore, reflecting an increase of 55.04% YoY from Rs 10.52 crore in Q1FY26 and a 69.90% QoQ growth from Rs 8.74 crore (before exceptional items) in Q4FY26. Net profit for the period in Q1FY27 was Rs 16.31 crore, showing a YoY growth of 55.04% against Rs 10.52 crore in Q1FY26 and a QoQ growth of 69.90% from Rs 9.60 crore in Q4FY26. Standalone Financial Highlights: Total income for Q1FY27 was Rs 383.52 crore, marking a 19.80% YoY increase from Rs 320.13 crore in Q1FY26 and a 2.09% QoQ decline from Rs 391.71 crore in Q4FY26. Revenue from operations was Rs 381.60 crore in Q1FY27, a YoY increase of 19.57% from Rs 319.15 crore in Q1FY26 and a QoQ decrease of 1.47% from Rs 387.29 crore in Q4FY26. Net profit for Q1FY27 stood at Rs 16.99 crore, representing a growth of 61.35% YoY from Rs 10.53 crore in Q1FY26 and a growth of 74.61% QoQ from Rs 9.73 crore in Q4FY26. Profit before tax reached Rs 16.99 crore in Q1FY27, compared to Rs 10.53 crore in Q1FY26 and Rs 8.87 crore (before exceptional items) in Q4FY26. Business Highlights: Rights Issue: As of June 30, 2026, the company raised Rs 442.73 crore out of a total rights issue size of Rs 449.95 crore. The funds raised through the first and final calls have been utilized as per the Letter of Offer, with a remaining unutilized balance of Rs 5.04 crore held in bank accounts. Demerger Proposal: The Board of Directors had previously granted in-principle approval on January 24, 2025, to explore the demerger of the CRAMS and Polymers business into an independent listed entity. To support this, the company incorporated Synthix Global Pharma Solutions Limited as a wholly-owned subsidiary on April 29, 2025. Going Concern and Financial Position: Although the Group has accumulated losses of Rs 286.21 crore as of June 30, 2026, the management has prepared the results on a going concern basis. This is supported by their confidence in renewing working capital facilities and increasing revenues and margins on products to meet future obligations. Sandeep Rao Managing Director & CEO, said: Q1FY27 was another quarter of resilient execution. Our overall Revenues stood at Rs 3,843 million, up 20% YoY; EBITDA at Rs 635 million, up 10% YoY and PAT at Rs 163 million, up 55% YoY. This is the highest EBITDA and PAT achieved in the last eighteen quarters. These results underscore the strength of our core business, disciplined execution and our continued focus on profitable growth. Our Base Business continues to exhibit robust momentum, supported by consistent operational execution and a focus on profitable growth. Our Base business Revenues stood at Rs 3,077 million, up 24% YoY; Gross margins of Rs 1,580 million, up 10% YoY and EBITDA at Rs 722 million, up 8% YoY; in spite of input cost pressures resulting from higher raw material prices on account of the ongoing geopolitical developments in West Asia. The sustained performance of the Base business reinforces our confidence in its long-term growth potential. The Commodity Ibuprofen business continues to face profitability challenges, reporting an EBITDA margin of negative 12% amid a difficult operating environment. While profitability remains under pressure, we witnessed a marginal sequential improvement during the quarter. Our ongoing efforts on strengthening the Balance sheet has led to reduction of net debt by Rs 1,346 million during the quarter bringing our net debt to Rs 4,795 million, resulting in a Net debt to EBITDA ratio of ~1.9 (annualised). Looking ahead, we remain committed to building on this strong foundation by driving sustainable growth, enhancing margins, and creating long-term value for our stakeholders through disciplined execution, operational excellence, and prudent capital allocation." Result PDF